Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
Stock
PRAX
PRAX News & Events
-
Add to Watchlist
Trade PRAX Autonomously
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Stock Price Prediction
Technical
Valuation
Financials
Earnings
Should I Buy
News & Events
PRAX News
B Group Acquires Stake in Bright Minds Biosciences
May 21 2026
Yahoo Finance
HighVista Strategies Cuts Stake in Viridian Therapeutics by $7 Million
May 17 2026
Yahoo Finance
Praxis Precision Medicines FDA Accepts New Drug Application for Ulixacaltamide
Apr 14 2026
seekingalpha
Praxis Precision Medicines' NDA for Ulixacaltamide Accepted by FDA
Apr 14 2026
NASDAQ.COM
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
Apr 14 2026
Newsfilter
PRAXIS PRECISION MEDICINES INC: RAYMOND JAMES BEGINS COVERAGE WITH A STRONG BUY RATING AND A TARGET PRICE OF $815
Apr 10 2026
moomoo
Praxis Precision Medicines Reports Promising Drug Results
Apr 06 2026
seekingalpha
Praxis Receives FDA Priority Review for Relutrigine
Mar 30 2026
Newsfilter
Show More News
PRAX Events
No data
PRAX Monitor News
Praxis Precision Medicines reaches 5-day high amid market gains
May 21 2026
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
Apr 17 2026
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
Apr 16 2026
Praxis Receives FDA Review Acceptance for Ulixacaltamide NDA
Apr 14 2026
Praxis Receives FDA Priority Review for Relutrigine
Mar 31 2026
Praxis Precision Medicines Inc. stock rises amid market gains
Mar 25 2026
Praxis Submits NDAs for Ulixacaltamide and Relutrigine
Feb 20 2026
Praxis Precision Medicines to Report Q4 and Full Year 2025 Financial Results
Feb 12 2026
Show More Monitor News
PRAX Earnings Analysis
No Data
People Also Watch
